ADA 2020: CGM Maker Dexcom Gains CE Mark, Launches G6 Pro While Rivalry With Abbott Builds

Dexcom’s CEO explained the company’s strategy for continued growth, including marketing opportunities for its G6 and G6 Pro continuous glucose monitors and plans for the next-gen G7 CGM.

Dexcom  G6 family

Just days before the 12 June start of the 80th virtual American Diabetes Association meeting, continuous glucose monitoring (CGM) company Dexcom Inc. announced its G6 CGM received a new CE marking in Europe and the launch of its G6 Pro CGM in the US.

The San Diego, CA-based CGM leader also recently gained temporary permission from US regulators to market its G6 CGM device in hospitals during the COVID-19 pandemic, which Dexcom’s CEO

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diabetic Care

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Roche To Localize CGM Manufacturing in US with $550M Indiana Site Investment

 
• By 

Roche’s Indianapolis site currently produces 5.2 billion Accu-Chek test strips annually and supports distribution to 53 countries. The new CGM line will add to an already diversified operational footprint, which includes R&D, laboratories, manufacturing, and IT services.

Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

 
• By 

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By 

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

More from Device Area

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show

 
• By 

Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.